Recombinant Human IL-12/IL-23 p40
| Code | Size | Price |
|---|
| LEI-I-395-10ug | 10 ug | £398.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
Ambient
Storage:
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Further Information
Format:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.4 containing 50 ug of bovine serum albumin per 1 ug of cytokine with no calcium, magnesium, or preservatives.
Formulation:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.4 containing 50 ug of bovine serum albumin per 1 ug of cytokine with no calcium, magnesium, or preservatives.
Long Description:
IL-12 plays a role in resistance against pathogens via the differentiation of naive T cells into Th1 cells. It stimulates the growth and function of T cells, blocks formation of new blood vessels, and contributes to antimycobacterial immune response. In addition, it promotes the production of IFN-γ and TNF-α and reduces IL-4 mediated suppression of IFN-γ. Consequently, this enhances the immunostimulatory and immunomodulatory effects of IFN-γ. In addition, there appears to be a link between IL-2 and the signal transduction of IL-12 in NK cells, which enhances the functional response of IL-12 via IFN-γ production and killing of target cells. Furthermore, IL-12 is thought to be associated with autoimmunity. IL-12 was shown to worsen the condition when administered to people already suffering from autoimmune diseases. Comparatively, inhibition of IL-12 (either through IL-12 gene knock-out in mice or treatment of mice with IL-12 mAbs) improved the disease.
Purity:
>90% by SDS-PAGE and analyzed by silver stain.
Target:
IL-12
References
1. Kapsenberg, ML. et al. (1997) J. Immunol. 159: 28 2. Ritz, J. et al. (2001) Blood. 97(12):3860-6.3. Barnes, PF. et al. (1994) J Clin Invest. 93(4):1733-9.
Related Products
| Product Name | Product Code | Supplier | Recombinant Mouse IL-12 | LEI-I-1180 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant Human IL-12 | LEI-I-214 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IL-12 - Biotin | LEI-I-267 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse IL-12 - Biotin | LEI-I-268 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IL-12 | LEI-I-329 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse IL-12 | LEI-I-330 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IL-12 (Clone 24910) | LEI-I-351 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IL-12 | LEI-I-851 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||